In a phase 1/2 study, adults with severe, treatment-refractory chronic #GVHD who received oral baricitinib achieved a high overall response rate at 6 months alongside significant improvements in quality of life

Source: Blood Advances

Full story: https://bit.ly/3Tsfuln

Dr. Marco Mielcarek at @fredhutch.org has received a five-year, $3.5 million NIH U01 collaborative research grant to complete a clinical trial for graft-vs.-host-disease.

💊 They aim to optimize drug dosage for #GVHD prevention: https://bit.ly/4AE8anl

GVHD can affect digestion after a donor-cell transplant. What changes should you report? Melissa Cochran, MS, APRN, AOCNP, covers symptoms and treatment. Watch or read:

bmtinfonet.org/video/graft-...

#GVHD

GVHD can affect the skin, gut, mouth and eyes after a donor-cell transplant. Shernan Holtan, MD, explains symptoms and when to tell your transplant team. Watch or read:

bmtinfonet.org/video/naviga...

#GVHD

$3.5M NIH grant supports a Fred Hutch-led clinical trial to find the optimal dose of PTCy, a drug used to help prevent #GVHD after bone marrow #transplant. Researchers will test whether lower doses can reduce side effects while maintaining benefits. https://bit.ly/4hd8MZu

📰 Sclerotic cGvHD: What Next? ➡️ Explore more in our Clinical Case of the Month: https://www.ebmt.org/ebmt/news/clinical-case-month-sclerotic-cgvhd-what-next

👥 Submitted by Sergio Rodriguez and Dennis Dong Hwan Kim, Princess Margaret Cancer Centre, University of Toronto, Canada

#GvHD #ClinicalCase

Shoutout to co-first authors Ajna Uzuni and Ximi Wang, and to Michael Pressler
@michaelppressler.bsky.social
. Thanks also to the McFaline-Figueroa Lab
@jlmcfalinefigueroa.bsky.social
for their support. Check out our paper!
#GVHD #SingleCell #TCR #SpatialTranscriptomics #Immunology

5/ We built #DecompTCR 🧬⏱️, a new model to resolve T-cell clonal dynamics over time 📈—revealing which clones persist, expand, or contract, and which temporal patterns are associated with #GVHD severity 🔍🔥.